Chester Davis, jumping ship from PhRMA, is new GPhA president
Former PhRMA exec will lead GPhA's push for biosimilar approvals
The Generic Pharmaceutical Assn. has appointed Chester “Chip” Davis as its new president and CEO, effective Aug. 18, succeeding G. Ralph Neas, Until now, Davis had been the EVP for advocacy at PhRMA, the trade association of research-based pharma companies.
When announcing, at the beginning of this year, his intention to leave office, Neas said that he intended to “explore leadership opportunities that have been presented to me regarding nonpartisan electoral reform and various entrepreneurial ventures in affordable health care, as well as the chance to resume part-time writing and teaching.” Davis has offered this statement: “"From policymakers to patients to providers, discussions on how to promote access while simultaneously generating health savings are taking center stage. Generic drugs, and soon biosimilars, play a vital role in holding down costs, and this industry's record of savings and access must not only continue, but flourish.”
The revolving door for public-private employment, in the year before national elections, is already in motion: Last week, the board of directors of America’s Health Insurance Plans (AHIP) unanimously elected Marily Tavenner as AHIP president and CEO; she was the administrator of CMS. Margaret Hamburg, FDA commissioner, stepped down in March, and has been replaced by Stephen Ostroff, MD, former FDA chief scientist, as acting commissioner.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
